期刊
CLINICAL RHEUMATOLOGY
卷 36, 期 2, 页码 451-455出版社
SPRINGER LONDON LTD
DOI: 10.1007/s10067-016-3417-4
关键词
Adalimumab; BDCAF; Behcet's disease; Biologics; Disease activity
类别
Our aim was to evaluate the effectiveness of adalimumab (ADA) during a 24-month study period in patients affected with Beh double dagger et's disease (BD). Clinical and therapeutic data from 100 consecutive BD patients treated with ADA were retrospectively collected and statistically analyzed. At 12-week follow-up, ADA induced clinical efficacy in 81 patients, with a mean time to response of 7.63 +/- 3.43 weeks; 25 (30.9 %) patients underwent a disease relapse after 22.17 +/- 1.57 months, but treatment adjustments allowed a recovery of efficacy in 11 cases. At 24-month follow-up, 67/100 patients were still on ADA therapy despite concomitant treatments. No differences were identified between ADA monotherapy and co-treatment with DMARDs about efficacy (p = 0.09), time to response (p = 0.61), relapses (p = 0.36), and ADA discontinuation (p = 0.40). No differences existed in patients switched from other tumor necrosis factor (TNF)-alpha inhibitors about efficacy at 12 weeks (p = 0.13) and rapidity of response (p = 0.93) while relapses (p = 0.01) and ADA discontinuation at 24 months (p = 0.001) were significantly more common. Adverse events occurred in 10 patients. ADA confirmed its effectiveness in BD. Combination therapy with DMARDs seems not significantly superior to monotherapy. Frequency and time to response for ADA was not conditioned by a previous lack or loss of efficacy to other TNF-alpha inhibitors, but long-term loss of efficacy seemed more likely in patients switched from other anti-TNF agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据